Timothy J. Collier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Timothy J. Collier has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Caryl E. Sortwell
Department of Neurological Sciences and the Research Center for Brain Repair, Rush Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA
3 shared publicationsJeffrey H. Kordower
2 shared publicationsJohn R. Sladek
2 shared publicationsAnita Fletcher-Turner
1 shared publicationB F Daley
1 shared publication- Caryl E. Sortwell
Department of Neurological Sciences, Research Center for Brain Repair, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612, USA
1 shared publication
Latest Publications
- 1 February 2005
- Published by Elsevier in Experimental Neurology
- Vol. 191, S60-S67
Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism
- 1 February 2005
- Published by Elsevier in Experimental Neurology
- Vol. 191, S60-S67
Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism
- 1 February 2004
- Published by Elsevier in Neurobiology of Aging
- Vol. 25 (2) , 209-221
Reduced cortical noradrenergic neurotransmission is associated with increased neophobia and impaired spatial memory in aged rats
- 1 February 2004
- Published by Elsevier in Neurobiology of Aging
- Vol. 25 (2) , 209-221
Reduced cortical noradrenergic neurotransmission is associated with increased neophobia and impaired spatial memory in aged rats
- 23 August 2003
- Published by Elsevier in Experimental Neurology
- Vol. 183 (2) , 258-262
Primate models of Parkinson's disease
- 23 August 2003
- Published by Elsevier in Experimental Neurology
- Vol. 183 (2) , 258-262
Primate models of Parkinson's disease
- 1 June 2003
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 991 (1) , 140-151
Cellular Models to Study Dopaminergic Injury Responses
Abstract:The study of immature midbrain dopamine (DA) neurons and dopaminergic cell lines in culture provides an opportunity to analyze mechanisms of cell death and avenues of potential intervention relevant to Parkinson's disease (PD) in a controlled environment. Use of cell culture models has provided evidence for different sets of intracellular changes associated with DA neuron death following exposure to the neurotoxins 6‐hydroxydopamine and MPP+, supporting roles for oxidative stress and impaired energy metabolism as significant factors endangering these cells. Interference with death of cultured DA neurons has provided an initial test system that has yielded all the identified neurotrophic factors for DA neurons. More recent work suggests that combinations of molecules secreted by myelinating glial cells and their precursors provide even greater neuroprotection for DA neurons. Most recently, culture systems have been used to implicate microglial activation in DA neuron injury, providing impetus to the investigation of antiinflammatory agents as potential therapeutics for PD. Thus, cell culture models provide an important bidirectional link between mechanistic studies and clinically relevant observations.
- 1 June 2003
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 991 (1) , 140-151
Cellular Models to Study Dopaminergic Injury Responses
Abstract:The study of immature midbrain dopamine (DA) neurons and dopaminergic cell lines in culture provides an opportunity to analyze mechanisms of cell death and avenues of potential intervention relevant to Parkinson's disease (PD) in a controlled environment. Use of cell culture models has provided evidence for different sets of intracellular changes associated with DA neuron death following exposure to the neurotoxins 6‐hydroxydopamine and MPP+, supporting roles for oxidative stress and impaired energy metabolism as significant factors endangering these cells. Interference with death of cultured DA neurons has provided an initial test system that has yielded all the identified neurotrophic factors for DA neurons. More recent work suggests that combinations of molecules secreted by myelinating glial cells and their precursors provide even greater neuroprotection for DA neurons. Most recently, culture systems have been used to implicate microglial activation in DA neuron injury, providing impetus to the investigation of antiinflammatory agents as potential therapeutics for PD. Thus, cell culture models provide an important bidirectional link between mechanistic studies and clinically relevant observations.
- 28 December 2001
- Published by Wiley in Journal of Comparative Neurology
- Vol. 442 (4) , 320-330
Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP‐treated monkeys: Feasibility relevant to multiple‐target grafting as a therapy for Parkinson's disease
Transplantation of embryonic dopamine (DA) neurons is being studied as an experimental replacement therapy for the DA‐deficiency characteristic of Parkinson's disease. Some studies suggest that one of the limitations of this approach is that intrastriatal placement of implants fails to consistently restore completely normal movement. One potential cause of this suboptimal therapeutic outcome is that changes in the neural activity of several structures in the basal ganglia circuitry resulting from striatal DA depletion is not adequately normalized by graft‐derived DA replacement in striatum alone. In the present study, we assessed the feasibility of grafting embryonic DA neurons into the substantia nigra (SN) of adult parkinsonian monkeys as an approach to restoration of the DA modulation of striatal‐nigral afferents that is lost after degeneration of SN neurons. Sixteen St. Kitts African green monkeys treated with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) received implants of embryonic monkey ventral mesencephalon (VM), or sham implants, aimed at the rostral SN. At 6 months after grafting, staining for tyrosine hydroxylase (TH) indicated that grafted DA neurons survived at this site, albeit often in reduced numbers compared with VM grafts to striatum. Grafted neurons extended neurites into the parenchyma of the SN, but there was no evidence of lengthy extension of graft‐derived neurites rostrally along the trajectory of the mesostriatal fiber system. A region‐specific, modest increase in DA levels and TH‐positive fiber density in the ventral‐medial putamen was detected, accompanied by modest but significant decreases in parkinsonian behaviors at 5–6 months after grafting. Our findings support the view that grafting embryonic tissue to the SN is a feasible procedure in nonhuman primates that provides a modest but detectable benefit of its own. These results encourage the further development of multiple‐target grafting strategies as a means of restoring modulation of anatomically widespread basal ganglia structures relevant to treatment of Parkinson's disease. J. Comp. Neurol. 442:320–330, 2002.
- 28 December 2001
- Published by Wiley in Journal of Comparative Neurology
- Vol. 442 (4) , 320-330
Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP‐treated monkeys: Feasibility relevant to multiple‐target grafting as a therapy for Parkinson's disease
Transplantation of embryonic dopamine (DA) neurons is being studied as an experimental replacement therapy for the DA‐deficiency characteristic of Parkinson's disease. Some studies suggest that one of the limitations of this approach is that intrastriatal placement of implants fails to consistently restore completely normal movement. One potential cause of this suboptimal therapeutic outcome is that changes in the neural activity of several structures in the basal ganglia circuitry resulting from striatal DA depletion is not adequately normalized by graft‐derived DA replacement in striatum alone. In the present study, we assessed the feasibility of grafting embryonic DA neurons into the substantia nigra (SN) of adult parkinsonian monkeys as an approach to restoration of the DA modulation of striatal‐nigral afferents that is lost after degeneration of SN neurons. Sixteen St. Kitts African green monkeys treated with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) received implants of embryonic monkey ventral mesencephalon (VM), or sham implants, aimed at the rostral SN. At 6 months after grafting, staining for tyrosine hydroxylase (TH) indicated that grafted DA neurons survived at this site, albeit often in reduced numbers compared with VM grafts to striatum. Grafted neurons extended neurites into the parenchyma of the SN, but there was no evidence of lengthy extension of graft‐derived neurites rostrally along the trajectory of the mesostriatal fiber system. A region‐specific, modest increase in DA levels and TH‐positive fiber density in the ventral‐medial putamen was detected, accompanied by modest but significant decreases in parkinsonian behaviors at 5–6 months after grafting. Our findings support the view that grafting embryonic tissue to the SN is a feasible procedure in nonhuman primates that provides a modest but detectable benefit of its own. These results encourage the further development of multiple‐target grafting strategies as a means of restoring modulation of anatomically widespread basal ganglia structures relevant to treatment of Parkinson's disease. J. Comp. Neurol. 442:320–330, 2002.
- 9 October 2000
- Vol. 426 (1) , 143-53
Oligodendrocyte-type 2 astrocyte-derived trophic factors increase survival of developing dopamine neurons through the inhibition of apoptotic cell death.
Survival of embryonic dopamine (DA) neurons is extremely low (5-20%) following transplantation. Strategies to increase this survival are critical to the future of transplantation for Parkinson's disease. We demonstrate here that a factor(s) released from striatal oligodendrocyte-type 2 astrocytes (SO2A) greatly improves the survival and phenotype expression of mesencephalic DA neurons in culture while simultaneously decreasing the presence of apoptotic nuclear profiles, as detected by the TUNEL method and bisbenzamide/tyrosine hydroxylase double labeling. This SO2A-derived trophic factor(s) has minimal effects on glia and no effect on nondopaminergic mesencephalic neurons. The developmental period during which this SO2A trophic effect occurs (E14-18) coincides with the period when mesencephalic grafts are undergoing the highest rates of apoptosis, i.e., immediately following implantation. Therefore, SO2A-derived trophic factor(s) offers great potential for the augmentation of grafted DA neuron survival.
- 9 October 2000
- Vol. 426 (1) , 143-53
Oligodendrocyte-type 2 astrocyte-derived trophic factors increase survival of developing dopamine neurons through the inhibition of apoptotic cell death.
Survival of embryonic dopamine (DA) neurons is extremely low (5-20%) following transplantation. Strategies to increase this survival are critical to the future of transplantation for Parkinson's disease. We demonstrate here that a factor(s) released from striatal oligodendrocyte-type 2 astrocytes (SO2A) greatly improves the survival and phenotype expression of mesencephalic DA neurons in culture while simultaneously decreasing the presence of apoptotic nuclear profiles, as detected by the TUNEL method and bisbenzamide/tyrosine hydroxylase double labeling. This SO2A-derived trophic factor(s) has minimal effects on glia and no effect on nondopaminergic mesencephalic neurons. The developmental period during which this SO2A trophic effect occurs (E14-18) coincides with the period when mesencephalic grafts are undergoing the highest rates of apoptosis, i.e., immediately following implantation. Therefore, SO2A-derived trophic factor(s) offers great potential for the augmentation of grafted DA neuron survival.
- 1 January 1999
- Published by Springer Nature in Drugs & Aging
- Vol. 14 (4) , 261-287
Therapeutic Potential of Nerve Growth Factors in Parkinson??s Disease
Parkinson’s disease (PD) is a neurodegenerative syndrome which primarily affects dopamine-producing neurons of the substantia nigra, resulting in poverty and slowness of movement, instability of gait...
- 1 January 1999
- Published by Springer Nature in Drugs & Aging
- Vol. 14 (4) , 261-287
Therapeutic Potential of Nerve Growth Factors in Parkinson??s Disease
Parkinson’s disease (PD) is a neurodegenerative syndrome which primarily affects dopamine-producing neurons of the substantia nigra, resulting in poverty and slowness of movement, instability of gait...